RHYTHM PHARMACEUTICALS INC (RYTM) Stock Fundamental Analysis

NASDAQ:RYTM • US76243J1051

90.94 USD
-4 (-4.21%)
Last: Mar 3, 2026, 01:45 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

RYTM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. RYTM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RYTM shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year RYTM has reported negative net income.
  • RYTM had a negative operating cash flow in the past year.
  • In the past 5 years RYTM always reported negative net income.
  • RYTM had a negative operating cash flow in each of the past 5 years.
RYTM Yearly Net Income VS EBIT VS OCF VS FCFRYTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -42.05%, RYTM is in line with its industry, outperforming 56.73% of the companies in the same industry.
  • RYTM has a Return On Equity (-74.78%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -42.05%
ROE -74.78%
ROIC N/A
ROA(3y)-55%
ROA(5y)-46.69%
ROE(3y)-114.78%
ROE(5y)-87.47%
ROIC(3y)N/A
ROIC(5y)N/A
RYTM Yearly ROA, ROE, ROICRYTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • RYTM's Gross Margin of 89.73% is amongst the best of the industry. RYTM outperforms 91.54% of its industry peers.
  • RYTM's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for RYTM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.46%
GM growth 5YN/A
RYTM Yearly Profit, Operating, Gross MarginsRYTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • RYTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RYTM has more shares outstanding
  • The number of shares outstanding for RYTM has been increased compared to 5 years ago.
  • RYTM has a better debt/assets ratio than last year.
RYTM Yearly Shares OutstandingRYTM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
RYTM Yearly Total Debt VS Total AssetsRYTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 14.55 indicates that RYTM is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 14.55, RYTM belongs to the best of the industry, outperforming 86.15% of the companies in the same industry.
  • A Debt/Equity ratio of 0.37 indicates that RYTM is not too dependend on debt financing.
  • The Debt to Equity ratio of RYTM (0.37) is worse than 69.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z 14.55
ROIC/WACCN/A
WACC8.53%
RYTM Yearly LT Debt VS Equity VS FCFRYTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • RYTM has a Current Ratio of 4.41. This indicates that RYTM is financially healthy and has no problem in meeting its short term obligations.
  • RYTM's Current ratio of 4.41 is in line compared to the rest of the industry. RYTM outperforms 50.77% of its industry peers.
  • RYTM has a Quick Ratio of 4.16. This indicates that RYTM is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.16, RYTM is in line with its industry, outperforming 50.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.41
Quick Ratio 4.16
RYTM Yearly Current Assets VS Current LiabilitesRYTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 30.73% over the past year.
  • Looking at the last year, RYTM shows a very strong growth in Revenue. The Revenue has grown by 21.57%.
  • RYTM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 100.22% yearly.
EPS 1Y (TTM)30.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.39%
Revenue 1Y (TTM)21.57%
Revenue growth 3Y100.22%
Revenue growth 5YN/A
Sales Q2Q%36.87%

3.2 Future

  • RYTM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.42% yearly.
  • RYTM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 61.38% yearly.
EPS Next Y0.84%
EPS Next 2Y36.29%
EPS Next 3Y49.84%
EPS Next 5Y43.42%
Revenue Next Year56.03%
Revenue Next 2Y70.17%
Revenue Next 3Y70.65%
Revenue Next 5Y61.38%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RYTM Yearly Revenue VS EstimatesRYTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
RYTM Yearly EPS VS EstimatesRYTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • RYTM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RYTM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RYTM Price Earnings VS Forward Price EarningsRYTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RYTM Per share dataRYTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • RYTM's earnings are expected to grow with 49.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.29%
EPS Next 3Y49.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RYTM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RHYTHM PHARMACEUTICALS INC

NASDAQ:RYTM (3/3/2026, 1:45:06 PM)

90.94

-4 (-4.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-09
Earnings (Next)05-05
Inst Owners105.22%
Inst Owner Change3.09%
Ins Owners0.66%
Ins Owner Change1.03%
Market Cap6.21B
Revenue(TTM)189.76M
Net Income(TTM)-201.92M
Analysts85.45
Price Target142.61 (56.82%)
Short Float %9.28%
Short Ratio8.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.92%
Min EPS beat(2)-11.05%
Max EPS beat(2)12.89%
EPS beat(4)1
Avg EPS beat(4)-5.05%
Min EPS beat(4)-13.18%
Max EPS beat(4)12.89%
EPS beat(8)4
Avg EPS beat(8)-1.22%
EPS beat(12)6
Avg EPS beat(12)-0.81%
EPS beat(16)9
Avg EPS beat(16)1.78%
Revenue beat(2)1
Avg Revenue beat(2)0.6%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)2.02%
Revenue beat(4)2
Avg Revenue beat(4)-2.57%
Min Revenue beat(4)-20.47%
Max Revenue beat(4)8.98%
Revenue beat(8)4
Avg Revenue beat(8)-1.22%
Revenue beat(12)5
Avg Revenue beat(12)0.12%
Revenue beat(16)7
Avg Revenue beat(16)13.77%
PT rev (1m)1.12%
PT rev (3m)11.72%
EPS NQ rev (1m)0.58%
EPS NQ rev (3m)-2%
EPS NY rev (1m)0.34%
EPS NY rev (3m)-6.13%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)1.72%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)1.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 32.73
P/FCF N/A
P/OCF N/A
P/B 23
P/tB 23.46
EV/EBITDA N/A
EPS(TTM)-3.11
EYN/A
EPS(NY)-3.08
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS2.78
BVpS3.95
TBVpS3.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.05%
ROE -74.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.73%
FCFM N/A
ROA(3y)-55%
ROA(5y)-46.69%
ROE(3y)-114.78%
ROE(5y)-87.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.46%
GM growth 5YN/A
F-Score5
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.23%
Cap/Sales 0.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.41
Quick Ratio 4.16
Altman-Z 14.55
F-Score5
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.39%
EPS Next Y0.84%
EPS Next 2Y36.29%
EPS Next 3Y49.84%
EPS Next 5Y43.42%
Revenue 1Y (TTM)21.57%
Revenue growth 3Y100.22%
Revenue growth 5YN/A
Sales Q2Q%36.87%
Revenue Next Year56.03%
Revenue Next 2Y70.17%
Revenue Next 3Y70.65%
Revenue Next 5Y61.38%
EBIT growth 1Y52.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.58%
OCF growth 3YN/A
OCF growth 5YN/A

RHYTHM PHARMACEUTICALS INC / RYTM FAQ

What is the fundamental rating for RYTM stock?

ChartMill assigns a fundamental rating of 4 / 10 to RYTM.


What is the valuation status of RHYTHM PHARMACEUTICALS INC (RYTM) stock?

ChartMill assigns a valuation rating of 1 / 10 to RHYTHM PHARMACEUTICALS INC (RYTM). This can be considered as Overvalued.


How profitable is RHYTHM PHARMACEUTICALS INC (RYTM) stock?

RHYTHM PHARMACEUTICALS INC (RYTM) has a profitability rating of 2 / 10.


How financially healthy is RHYTHM PHARMACEUTICALS INC?

The financial health rating of RHYTHM PHARMACEUTICALS INC (RYTM) is 5 / 10.


Can you provide the expected EPS growth for RYTM stock?

The Earnings per Share (EPS) of RHYTHM PHARMACEUTICALS INC (RYTM) is expected to grow by 0.84% in the next year.